Advertisement
U.S. markets closed

Helius Medical Technologies, Inc. (HSDT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.83+0.23 (+4.11%)
At close: 04:00PM EDT
5.84 +0.01 (+0.17%)
After hours: 05:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.60
Open5.62
Bid5.51 x 900
Ask6.21 x 1000
Day's Range5.58 - 5.90
52 Week Range4.29 - 14.45
Volume10,202
Avg. Volume315,522
Market Cap5.17M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-11.83
Earnings DateMar 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HSDT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Helius Medical Technologies, In
    Daily Spotlight: Dollar Back at HighsThe dollar is up 8% year-to-date and back at cycle highs. The greenback spiked early in the pandemic as global investors flocked to the security of assets denominated in U.S. currency. Indeed, the dollar in 2020 surpassed cycle highs set initially in 2001-2002 and then again in late 2016. But after peaking in April 2020, the greenback declined into 2021. And now in 2022 -- in the wake of the Russian invasion of Ukraine, spiking inflation, and rising global interest rates -- has surpassed cycle highs. Currently, on a real trade-weighted basis, the dollar is 20% above the average valuation over the past 20 years. The fully valued U.S. currency reflects several factors, but primarily the relative strength of the U.S. economy and global investor confidence in the U.S. as the world economy recovers from COVID-19 and battles high prices. We anticipate a trading range around current levels for the greenback for the balance of this year. That's because we think U.S. GDP will start to cool as the Fed has lifted the federal funds rate to tame inflation. What's more, with Treasury prices likely headed lower as the Fed addresses inflation, investors may be selling T-bills and bonds. Lastly, the lofty current valuation of the greenback implies that other currencies -- even gold or other commodities -- are possibly undervalued, and we would expect traders to bid up those values over time.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

    -- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for the Portable

  • GlobeNewswire

    Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

    NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial

  • GlobeNewswire

    Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

    -- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors ---- Results will support efforts to achieve U.S. authorization under PoNS’s breakthrough designation for stroke -- NEWTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on del